All In Biotech

Drug Trial Radar · NCT04964934

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 315 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

315

Actual

Start

Jun 30, 2021

Primary completion

Jun 30, 2025

Study completion Sep 1, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.

Conditions

  • ER-Positive HER2-Negative Breast Cancer

Interventions

  • AZD9833Drug

    Dosage formulation: AZD9833 tablets will be administered orally

  • AZD9833 PlaceboDrug

    Dosage formulation: AZD9833 placebo tablets will be administrated orally.

  • AnastrozoleDrug

    Dosage formulation: anastrozole tablets will be administered orally.

  • Anastrozole placeboDrug

    Dosage formulation: anastrozole placebo tablets will be administrated orally.

  • LetrozoleDrug

    Dosage formulation: letrozole tablets will be administered orally.

  • Letrozole placeboDrug

    Dosage formulation: letrozole placebo tablets will be administered orally.

  • PalbociclibDrug

    Dosage formulation: palbociclib tablets/capsules will be administered orally

  • AbemaciclibDrug

    Dosage formulation: abemaciclib tablets will be administered orally

  • Luteinizing hormone-releasing hormone (LHRH) agonistDrug

    Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.

  • RibociclibDrug

    Dosage formulation: ribociclib tablets will be administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1)Time frame: From randomization until the earlier of the progression event or death (approximately 2 years)

Locations

264 sites in 23 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Hot Springs, Arkansas

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Long Beach, California

  • Research Site

    San Diego, California

  • Research Site

    Santa Rosa, California

  • Research Site

    Grand Junction, Colorado

  • Research Site

    Lone Tree, Colorado

  • Research Site

    Fort Myers, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Park Ridge, Illinois

  • Research Site

    Fort Wayne, Indiana

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Baltimore, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Fairhaven, Massachusetts

  • Research Site

    Foxborough, Massachusetts

  • Research Site

    Milford, Massachusetts

  • Research Site

    South Weymouth, Massachusetts

  • Research Site

    Detroit, Michigan

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    Rochester, Minnesota

  • Research Site

    Oxford, Mississippi

  • Research Site

    Kansas City, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Billings, Montana

  • Research Site

    Omaha, Nebraska

  • Research Site

    Camden, New Jersey

  • Research Site

    Ridgewood, New Jersey

  • Research Site

    Brooklyn, New York

  • Research Site

    East Syracuse, New York

  • Research Site

    New Hyde Park, New York

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Shirley, New York

Showing 40 of 264 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.